News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Patient expectation is a strong predictor of severe nausea after chemotherapy


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www3.interscience.wiley.com/cgi-bin/abstract/109745724/ABSTRACT

Posted on: 11/19/2004

Patient expectation is a strong predictor of severe nausea after chemotherapy

Original Article

A University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma



Joseph A. Roscoe, Ph.D. 1 *, Peter Bushunow, M.D. 2, Gary R. Morrow, Ph.D., M.S. 1, Jane T. Hickok, M.D., M.P.H. 1, Philip J. Kuebler, M.D., Ph.D. 3, Andrew Jacobs, M.D. 4, Tarit K. Banerjee, M.D. 5 1Behavioral Medicine Unit, University of Rochester Community Clinical Oncology Program Research Base, University of Rochester James P. Wilmot Cancer Center, Rochester, New York 2Rochester General Hospital Cancer Center, Rochester, New York 3Columbus Community Clinical Oncology Program, Columbus, Ohio 4Virginia Mason Research Center Community Clinical Oncology Program, Seattle, Washington 5Marshfield Clinic Research Foundation Community Clinical Oncology Program, Marshfield, Wisconsin

email: Joseph A. Roscoe (Joseph_Roscoe@urmc.rochester.edu)

*Correspondence to Joseph A. Roscoe, Behavioral Medicine Unit, University of Rochester Community Clinical Oncology Program Research Base, University of Rochester James P. Wilmot Cancer Center, 601 Elmwood Avenue, P.O. Box 704, Rochester, NY 14642

Fax: (585) 461-5601

Funded by: National Cancer Institute; Grant Number: U10CA 37420

Keywords response expectancy • expectation • chemotherapy • nausea • emesis • doxorubicin

Abstract

BACKGROUND

Patients may use their past experiences with nausea, as well as information about the incidence of nausea from chemotherapy that other patients have experienced, to form a prediction, or response expectancy, of nausea from their own upcoming chemotherapy. Mounting evidence suggests that these expectancies relating to nausea are significant predictors, and, likely, contributing factors to the development of treatment-related nausea.

METHODS

The patients in the current study were participants in the control arm of a multicenter clinical trial conducted between November 1999 and July 2001 by the University of Rochester Community Clinical Oncology Program. All patients in the current report were age 18 years and were about to begin a first cancer treatment regimen containing doxorubicin.

RESULTS

Expectancy of nausea assessed before patients received their first doxorubicin-based chemotherapy treatment was found to be a strong predictor of subsequent nausea and in fact was stronger than previously reported predictive factors, including age, nausea during pregnancy, and susceptibility to motion sickness. Women who believed it was very likely that they would have severe nausea from chemotherapy were five times more likely to experience severe nausea than fellow patients who thought its occurrence would be very unlikely.

CONCLUSIONS

Further studies confirming an expectancy of nausea as a risk factor are warranted as are studies examining the benefit to a patient's quality of life from modifying antiemetic treatment guidelines to take into account symptom expectancies. Finally, ethically acceptable interventions that are designed to reduce patients' nausea expectancies or increase their expectancies of nausea control should be developed and studied. Cancer 2004. © 2004 American Cancer Society.

-------------------------------------------------------------------------------- Received: 1 July 2004; Revised: 20 August 2004; Accepted: 8 September 2004



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740